Instrument Inactif

Communiqués CHF Solutions Nasdaq

Actions

Equipement et technologie médicale avancés

Communiqués

06/08	Nuwellis Strengthens Product Development Organization with Appointment of Dale Brady as Principal R&D Engineer	AQ
04/08	Nuwellis Announces Next-Generation Aquadex Platform Strategy to Expand Future Critical Care Applications	AQ
31/07	Nuwellis Announces Pricing of $3.4 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules	AQ
30/07	Nuwellis Inc. (NASDAQ: NUWE) Surges on Pediatric Cardiorenal Expansion as Oversold Stocks Take Center Stage - See Inside	AQ
30/07	Nuwellis Announces Acceptance by Frontiers in Pediatrics of New Single-Center Retrospective Study Supporting Alternative Anticoagulation Strategy for Aquadex Ultrafiltration Therapy	AQ
28/07	Nuwellis Expands Pediatric Footprint with First Aquadex SmartFlow® Installations in Wisconsin	AQ
27/07	Nuwellis Announces Preliminary Revenue Results for the Second Quarter 2026 Showing Double Digit Growth	AQ
16/07	Nuwellis Awarded U.S. Patent for Novel Catheter Technology Designed to Enhance Extracorporeal Therapies	AQ
07/07	Nuwellis to Showcase Aquadex Therapy at KidneyBee Summit 2026	AQ
26/06	Nuwellis Celebrates Five Years of Support of the Pediatric Cardiac Critical Care Consortium (PC⁴)	AQ
25/06	Nuwellis Announces Pediatric Expansion in Michigan with First Aquadex SmartFlow® Installations	AQ
24/06	Incoming Nuwellis CEO Mike McCormick Underscores Strategic Priorities for Continued Market Expansion in Pediatric Category and Revenue Generation in Letter to Shareholders	AQ
18/06	Nuwellis Expands Critical Care Education with Aquadex Training at University of Minnesota Critical Care Cardiology Education Summit	AQ
16/06	Nuwellis Appoints Mike McCormick as Chief Executive Officer	AQ
10/06	Nuwellis Expands Collaboration with Major South Carolina Healthcare System to Install New Aquadex SmartFlow® Devices at One of its Children’s Hospitals	AQ
09/06	Nuwellis Announces Closing of $6.0 Million Registered Public Offering	AQ
05/06	Nuwellis Announces Pricing of $6 Million Public Offering	AQ
14/05	Nuwellis Announces Successful Completion of FDA Pre-Submission 510(k) Meeting to Expand Aquadex Label	AQ
12/05	Nuwellis, Inc. Announces First Quarter 2026 Financial Results	AQ
05/05	Nuwellis, Inc. To Announce First Quarter 2026 Financial Results on May 12, 2026	AQ
29/04	Nuwellis Highlights Case Study Featuring Precision Ultrafiltration Therapy in Pediatric Cardiorenal Care at ISHLT 2026 Annual Meeting	AQ
28/04	Nuwellis Announces Receipt of a Notice of Allowance from the U.S. Patent and Trademark Office for Innovative Dual Lumen Midline Catheter Technology	AQ
23/04	Nuwellis to Participate in the AATS 106th Annual Meeting and ERAS Cardiac Spring Retreat	AQ
21/04	Nuwellis Announces Aquadex Software Update	AQ
16/04	Nuwellis Welcomes Back Three Former Team Members to Accelerate Commercial and Clinical Momentum	AQ